Competent Cells Market
The Global Competent Cells Market will grow at a CAGR of 10% from 2018 to 2023 to reach USD 2,318.6
million by 2023, according to this latest publication from Meticulous Research®.
The global competent cells market is driven by various factors such as growing
demand for recombinant proteins & molecular cloned products, advancement in
molecular cloning research with emergence of new technologies, and rising
government initiatives and funding for life science research.
Key Opportunities and
Challenges for the Competent cells Market
Emerging economies such
as Latin America, Asia Pacific, & Africa provides significant opportunities
for various stakeholders in this market. However, increasing recombinational
and cloning based applications simultaneously enhance the need for maintenance
of laboratory transformation parameters; thereby challenging the growth of
competent cells market to some extent.
Browse
in-depth Report on https://www.meticulousresearch.com/product/competent-cells-market-forecast-2023/
Key Market Segments to
Watch
The global competent
cells market is mainly categorized by type (cloned competent cells,
Agrobacterium tumefaciens competent cells, expression competent cells),
treatment (chemically competent cells and electrocompetent cells), application
(cloning, protein expression, others), end user (pharmaceutical &
biotechnology industry, academics & research institutes, and contract
research organizations), and geography.
On the basis of type,
cloned competent cells commanded the largest share in the global competent
cells market in 2017, mainly due to their rising adoption in research with increasing
feasibility of genetic therapy, need for rapid diagnosis & treatment,
favorable government support for cloning based research in various countries,
and rising availability of sophisticated instruments and technology.
On the basis of
treatment, chemically competent cells held the largest share in the global
competent cells market in 2017. This was mainly attributed to the rising need
for cost effective experimental protocol with growing demand for recombinant
proteins and molecular cloned products, and rising intensity of cell based
research. Chemically competent cells have been commonly used for transformation
and vector based molecular cloning experiments because the treatment of
competent cells through chemicals is very simple, faster, cost effective, and
does not require any specialized equipment.
On the basis of application,
cloning accounted for the largest share in the global competent cells market in
2017. The large share of this market is mainly attributed to various
advancements in recombinant technology, increasing government support for
cloning based research, and rising R&D funding for cell based research.
Based on end user,
pharmaceutical and biotechnology industry commanded the largest share in the
global competent cells market in 2017, mainly due to higher adoption of
competent cells by pharmaceutical & biotechnology companies with growing
demand for molecular cloning with advancements in the cloning technologies, and
rising investments in research & development to fulfill the demand for
protein based therapeutics.
Key players in the global
market
The key players in the
global competent cells market are Thermo Fisher Scientific, Inc., Agilent Technologies,
Inc., Bio-Rad Laboratories, Inc., Merck & Company, Inc., Illumina, Inc.,
Promega Corporation, New England Biolabs, OriGene Technologies, Inc., Zymo
Research Corporation, Scarab Genomics, LLC, Meridian Bioscience, Inc., Delphi
Genetics S.A., Qiagen N.V., Cell Applications, Inc., GenScript Biotech
Corporation, and Takara Holdings Inc.
Contact
Us:
Viren Shrivastava
Viren Shrivastava
AVP-
Global Sales and Marketing
Meticulous
Research®
Tel:
+1-646-781-8004
Email:
viren@meticulousresearch.com
Comments
Post a Comment